Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BAC
|
|||
| Former ID |
DIB014030
|
|||
| Drug Name |
Revacept
|
|||
| Synonyms |
Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
Click to Show/Hide
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Phase 2 | [1] | |
| Company |
ProCorde GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Platelet glycoprotein VI (GP6) | Target Info | Inhibitor | [2] |
| KEGG Pathway | ECM-receptor interaction | |||
| Platelet activation | ||||
| Reactome | GPVI-mediated activation cascade | |||
| Cell surface interactions at the vascular wall | ||||
| Platelet Adhesion to exposed collagen | ||||
| WikiPathways | Platelet Adhesion to exposed collagen | |||
| GPVI-mediated activation cascade | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01645306) Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02). U.S. National Institutes of Health. | |||
| REF 2 | Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.